Effect of Dexmedetomidine Combined With Sufentanil for Postoperative Intravenous Analgesia in Neurosurgery
NCT ID: NCT02552459
Last Updated: 2016-10-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
120 participants
INTERVENTIONAL
2015-09-30
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Multicenter Study: Dexmedetomidine Combined With Sufentanil for Patient Controlled Intravenous Analgesia After Caesarean Section
NCT02741219
Whether Dexmedetomidine Can Improve the Prognosis of Elderly Patients With Postoperative Cognitive Dysfunction
NCT02923128
Effect of Dezocine Combined With Sufentanil on the Quality of Postoperative Recovery and Analgesic Effect in Patients Undergoing Thoracic Surgery
NCT06439368
Small-dose Dexmedetomidine Effects on Recovery Profiles of Supratentorial Tumors Patients From General Anesthesia
NCT02007798
The Neuroprotective Effects of Dexmedetomidine During Brain Surgery
NCT02878707
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
sufentanil
sufentanil 150μg，intravenous administration during the following 72 hours after operation.
Sufentanil
sufentanil 150μg， intravenous administration during post-operative 72 hours.
sufentanil&dexmedetomidine 1
sufentanil 150μg，dexmedetomidine 0.05μg/kg/h，intravenous administration during the following 72 hours after operation.
Sufentanil
sufentanil 150μg， intravenous administration during post-operative 72 hours.
dexmedetomidine 1
dexmedetomidine 0.05μg/kg/h, Continuous intravenous injection for 72 hours after operation
sufentani&dexmedetomidine 2
sufentanil 150μg，dexmedetomidine 0.1μg/kg/h，intravenous administration during the following 72 hours after operation.
Sufentanil
sufentanil 150μg， intravenous administration during post-operative 72 hours.
dexmedetomidine 2
dexmedetomidine 0.1μg/kg/h, Continuous intravenous injection for 72 hours after operation
sufentanil&dexmedetomidine 3
sufentanil 150μg，dexmedetomidine 0.15μg/kg/h ，intravenous administration during the following 72 hours after operation.
Sufentanil
sufentanil 150μg， intravenous administration during post-operative 72 hours.
dexmedetomidine 3
dexmedetomidine 0.15μg/kg/h, Continuous intravenous injection for 72 hours after operation recorded in the following 72h.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sufentanil
sufentanil 150μg， intravenous administration during post-operative 72 hours.
dexmedetomidine 1
dexmedetomidine 0.05μg/kg/h, Continuous intravenous injection for 72 hours after operation
dexmedetomidine 2
dexmedetomidine 0.1μg/kg/h, Continuous intravenous injection for 72 hours after operation
dexmedetomidine 3
dexmedetomidine 0.15μg/kg/h, Continuous intravenous injection for 72 hours after operation recorded in the following 72h.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. aged 18-65 years old.
3. operating time varies 1-4h,and extubation after the operation.
Exclusion Criteria
2. known for dexmedetomidine or other drugs allergy in this study.
3. cannot communicate.
4. preoperative systolic blood pressure \<90 mmHg, or the heart rate \<50/min.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
First Affiliated Hospital, Sun Yat-Sen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xinxin Shao
resident
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jiang Nan, doctor
Role: PRINCIPAL_INVESTIGATOR
The First Affiliated Hospital, Sun Yat-sen Unniversity
Shao Xinxin, master
Role: PRINCIPAL_INVESTIGATOR
The First Affiliated Hospital, Sun Yat-sen Unniversity
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
the First Affiliated Hospital of Sun Yetsen University
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FirstSunYetSen-jn2015
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.